4Filing Date: Aug 12, 2026

West Pharmaceutical Services (WST)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0000105770-26-000104
Total Value$1.09M
Trades6
Insiders1

Transaction Details

McMahon Robert W.
SVP & Chief Financial Officer·Direct
Exercise · Dispose
Rst. Stock UnitDerivative
Shares-794.47
Price$0.00
Total Value$0
Shares Owned After2.38K
Transaction DateAug 11, 2026
Footnotes ▸

Each restricted stock unit represents a contingent right to receive one share of WST common stock. | This award vests in four equal annual installments beginning on August 11, 2026. | This award vests in four equal annual installments beginning on August 11, 2026.

McMahon Robert W.
SVP & Chief Financial Officer·Direct
Tax W/H · Dispose
Common Stock
Shares-345.52
Price$351.37
Total Value$121.4K
Shares Owned After3.43K
Transaction DateAug 11, 2026
McMahon Robert W.
SVP & Chief Financial Officer·Direct
Exercise · Dispose
Rst. Stock UnitDerivative
Shares-6.35K
Price$0.00
Total Value$0
Shares Owned After2.12K
Transaction DateAug 11, 2026
Footnotes ▸

Each restricted stock unit represents a contingent right to receive one share of WST common stock. | On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. | On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date.

McMahon Robert W.
SVP & Chief Financial Officer·Direct
Tax W/H · Dispose
Common Stock
Shares-2.76K
Price$351.37
Total Value$971.1K
Shares Owned After7.02K
Transaction DateAug 11, 2026
McMahon Robert W.
SVP & Chief Financial Officer·Direct
Exercise · Acquire
Common Stock
Shares+794.47
Price-
Total Value$0
Shares Owned After3.77K
Transaction DateAug 11, 2026
Footnotes ▸

Each restricted stock unit represents a contingent right to receive one share of WST common stock.

McMahon Robert W.
SVP & Chief Financial Officer·Direct
Exercise · Acquire
Common Stock
Shares+6.35K
Price-
Total Value$0
Shares Owned After9.78K
Transaction DateAug 11, 2026
Footnotes ▸

Each restricted stock unit represents a contingent right to receive one share of WST common stock.

Post-Transaction Holdings

McMahon Robert W. · SVP & Chief Financial Officer
SecuritySharesChange
Common Stock3.43K+4.04K (-661.68%)
Rst. Stock Unit2.38K-7.15K (-75.00%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-08-11 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: WEST PHARMACEUTICAL SERVICES INC (WST) CIK: 0000105770 --- Reporting Owner --- Name: McMahon Robert W. CIK: 0001608730 Role: Officer (SVP & Chief Financial Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-08-11 | Code: M (Exercise of derivative) Shares: +794.469 Shares Owned After: 3,774.96 | Ownership: D (Direct) Footnotes: [F1] Each restricted stock unit represents a contingent right to receive one share of WST common stock. [Transaction #2] Security: Common Stock Date: 2026-08-11 | Code: F (Payment of exercise/tax) Shares: -345.515 | Price: $351.37 Total Value: $121,403.61 Shares Owned After: 3,429.445 | Ownership: D (Direct) [Transaction #3] Security: Common Stock Date: 2026-08-11 | Code: M (Exercise of derivative) Shares: +6,354.736 Shares Owned After: 9,784.181 | Ownership: D (Direct) Footnotes: [F1] Each restricted stock unit represents a contingent right to receive one share of WST common stock. [Transaction #4] Security: Common Stock Date: 2026-08-11 | Code: F (Payment of exercise/tax) Shares: -2,763.675 | Price: $351.37 Total Value: $971,072.48 Shares Owned After: 7,020.506 | Ownership: D (Direct) --- Derivative Transactions --- [Transaction #1] Security: Rst. Stock Unit Date: 2026-08-11 | Code: M (Exercise of derivative) Shares: -6,354.736 | Price: $0.00 Shares Owned After: 2,118.579 | Ownership: D (Direct) Footnotes: [F1] Each restricted stock unit represents a contingent right to receive one share of WST common stock. [F2] On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. [F2] On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. [Transaction #2] Security: Rst. Stock Unit Date: 2026-08-11 | Code: M (Exercise of derivative) Shares: -794.469 | Price: $0.00 Shares Owned After: 2,383.4 | Ownership: D (Direct) Footnotes: [F1] Each restricted stock unit represents a contingent right to receive one share of WST common stock. [F3] This award vests in four equal annual installments beginning on August 11, 2026. [F3] This award vests in four equal annual installments beginning on August 11, 2026. --- Footnotes (Complete Index) --- F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2: On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. F3: This award vests in four equal annual installments beginning on August 11, 2026. --- Signature --- /s/ /s/ Caitlin Hippeli, as an agent for Robert W. McMahon (2026-08-12)

keid analysis is for reference only and does not constitute investment advice.